Dyax and MorphoSys Sign License Agreement on Antibody-Related Patents
News Nov 21, 2007
The agreement grants MorphoSys a fully paid-up license to a variety of phage display-related patents from Dyax as well as other patents, including several relating to methods for displaying and selecting antibodies and other proteins through the use of alternative types of display.
As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for future technology development to further diversify its antibody technology portfolio and improve its offering for therapeutic, diagnostic and research customers. Financial terms were not disclosed.
Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, stated, “This agreement with MorphoSys recognizes the true value of our intellectual property portfolio as our powerful proprietary display technologies continue to be attractive to many companies in the biotechnology and pharmaceutical industry.”
Mr. Blair added, “We are pleased to have entered into this licensing agreement with MorphoSys.”
“We are very pleased about this agreement with Dyax, which provides us even greater flexibility for our future technology development plans,” commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
New Player in Alzheimer's Disease Pathogenesis IdentifiedNews
Using proteomics, microscopic analysis, and functional assays, scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check.READ MORE
Proteome of the Human Heart Mapped for the First TimeNews
Scientists have determined which and how many individual proteins are present in each type of cell that occurs in the heart. In doing so, they compiled the first atlas of the healthy human heart, known as the cardiac proteome. The atlas will make it easier to identify differences between healthy and diseased hearts in future.READ MORE